scholarly journals How does knowledge of three-dimensional excision margins following breast conservation surgery impact upon clinical target volume definition for partial-breast radiotherapy?

2010 ◽  
Vol 94 (3) ◽  
pp. 292-299 ◽  
Author(s):  
Anna M. Kirby ◽  
Philip M. Evans ◽  
Ashutosh Y. Nerurkar ◽  
Saral S. Desai ◽  
Jaroslaw Krupa ◽  
...  
2013 ◽  
Vol 1 (4) ◽  
pp. 197-201
Author(s):  
Rashi Agrawal ◽  
Dinesh Singh

Aim of study-Breast conservation surgery followed by radiotherapy has become the standard of care for early breast cancer. Total treatment time extends from6½ to 7 weeks. In radiotherapy such a long treatment duration is always worrisome. Simultaneous treatment of cavity and breast can reduce treatment time but we should consider acute and late toxicities. Materials and methods- In this study we are presenting data of 14consecutive patients of carcinoma left breast which were treated between March 2010 and June 2012.Dose prescribed to clinical target volume breast was 50 Gy in 25 fractions and CTV boost was 60 Gy in 25 fractions. Results-Clinical target volume for cavity ranged from 34.81cc to 369.8cc. Two patients (14.2%) had acute grade 2 skin toxicity and all other (85.7%) grade 1. Higher dose in boost region did not produce differential fibrosis or edema of breast. Median follow up is 26 months. None of our patients has experienced cardiac or pulmonary toxicity till date and all are in regular follow up. Conclusion-With simultaneous integrated boost in carcinoma breast patients, overall treatment time can be reduced without increasing early and late toxicities. Accrual of more patients is continuing. DOI: http://dx.doi.org/10.3126/ijasbt.v1i4.8794   Int J Appl Sci Biotechnol, Vol. 1(4): 197-201


2010 ◽  
Vol 92 (7) ◽  
pp. 562-568 ◽  
Author(s):  
Siong-Seng Liau ◽  
Massimiliano Cariati ◽  
David Noble ◽  
Charles Wilson ◽  
Gordon C Wishart

INTRODUCTION The risk of ipsilateral breast tumour recurrence (IBTR) following breast conservation surgery (BCS) for invasive breast cancer (IBC) and radiotherapy is dependent on patient-, tumour- and treatment-related variables. In the Cambridge Breast Unit, breast conserving surgery has been performed with a target radial margin of 5 mm for IBC, in combination with 40-Gy hypofractionated (15 fractions) breast radiotherapy, since 1999. PATIENTS AND METHODS An audit was performed of cases treated between 1999 and 2004. A total of 563 patients underwent BCS for invasive breast cancer with 90.4% receiving radiotherapy (RT) and 60.4% of patients receiving boost RT (3 fractions of 3-Gy). RESULTS After a median follow-up of 58 months, five of the 563 (0.9%) patients developed IBTR. The 5-year actuarial IBTR rate was 1.1%. In terms of distant disease recurrence (DDR), 29 of the 563 (5.2%) had DDR during follow-up, giving a 5-year actuarial DDR rate of 5.4%. The 5-year breast cancer specific survival was 95%, with the poorer NPI groups having worse breast cancer specific survival (Log-rank, P < 0.0001). More importantly, patients with IBTR had a shorter breast cancer-specific survival than those who were IBTR-free (Log-rank, P < 0.0001). CONCLUSIONS Our treatment regimen, combining BCS with a 5-mm target margin and hypofractionated 40-Gy RT, results in an extremely low rate of IBTR, and compares favourably with the target IBTR rate of < 5% defined by the Association of Breast Surgeons (ABS) at BASO guidelines.


Sign in / Sign up

Export Citation Format

Share Document